| October 15, 2026 |
A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treatment of Moderate to Severe Forehead Lines (FHL) in Adult Participants |
Trial Milestone |
Phase 2 |
| November 15, 2026 |
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab |
Trial Milestone |
Phase 2 |
| December 15, 2026 |
A Study to Evaluate the Safety and Pharmacokinetics of Multiple Doses Upadacitinib, Tofacitinib, and Baricitinib in Healthy Adult Volunteers |
Trial Milestone |
Phase 1 |
| December 15, 2026 |
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa |
Trial Milestone |
Phase 3 |
| January 15, 2027 |
A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) |
Trial Milestone |
Phase 2/Phase 3 |
| January 15, 2027 |
Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis |
Trial Milestone |
Phase 1 |
| January 15, 2027 |
Study to Evaluate Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-291 Moves Through the Body in Adult Participants With Non-Hodgkin's Lymphoma |
Trial Milestone |
Phase 1 |
| January 15, 2027 |
A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity. |
Trial Milestone |
Phase 1 |
| February 15, 2027 |
IMGN632 as Monotherapy or With Venetoclax and/or Azacitidine for Participants With CD123-Positive Acute Myeloid Leukemia |
Trial Milestone |
Phase 1/Phase 2 |
| February 15, 2027 |
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers |
Trial Milestone |
Phase 1 |
| February 15, 2027 |
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab |
Trial Milestone |
Phase 2 |
| February 15, 2027 |
A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression |
Trial Milestone |
Phase 2 |
| March 15, 2027 |
Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder |
Trial Milestone |
Phase 2 |
| March 15, 2027 |
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) |
Trial Milestone |
Phase 2 |
| March 15, 2027 |
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. |
Trial Milestone |
Phase 3 |
| April 15, 2027 |
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Single Ascending Doses of ABBV-1451 Infusions and Injections in Healthy Adult Participants |
Trial Milestone |
Phase 1 |
| May 15, 2027 |
Study to Assess Adverse Events and How Oral ABBV-1162 Moves Through the Body of Healthy Adults |
Trial Milestone |
Phase 1 |
| May 15, 2027 |
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults. |
Trial Milestone |
Phase 1 |
| May 15, 2027 |
A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer |
Trial Milestone |
Phase 1 |
| June 15, 2027 |
Study to Assess Participant Satisfaction After Jawline and Neck Treatment |
Trial Milestone |
Phase 4 |
| July 15, 2027 |
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome |
Trial Milestone |
Phase 3 |
| July 15, 2027 |
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan |
Trial Milestone |
Phase 1 |
| July 15, 2027 |
Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe Pain |
Trial Milestone |
Phase 3 |
| August 15, 2027 |
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab |
Trial Milestone |
Phase 3 |
| September 15, 2027 |
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 |
Trial Milestone |
Phase 1 |
| November 15, 2027 |
Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab |
Trial Milestone |
Phase 1 |
| December 15, 2027 |
A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy |
Trial Milestone |
Phase 2 |
| December 15, 2027 |
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis |
Trial Milestone |
Phase 2 |
| December 15, 2027 |
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma |
Trial Milestone |
Phase 3 |
| January 15, 2028 |
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia |
Trial Milestone |
Phase 2 |
| February 15, 2028 |
A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants |
Trial Milestone |
Phase 1 |
| February 15, 2028 |
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Immunoglobulin Light Chain (AL) Amyloidosis Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion |
Trial Milestone |
Phase 1/Phase 2 |
| February 15, 2028 |
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Trial Milestone |
Phase 2 |
| March 15, 2028 |
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) |
Trial Milestone |
Phase 3 |
| March 15, 2028 |
Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities |
Trial Milestone |
Phase 2 |
| March 15, 2028 |
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo |
Trial Milestone |
Phase 3 |
| April 15, 2028 |
A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) |
Trial Milestone |
Phase 1 |
| June 15, 2028 |
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines |
Trial Milestone |
Phase 2 |
| August 15, 2028 |
A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK) |
Trial Milestone |
Phase 3 |
| November 15, 2028 |
Study of AGN-151607-DP to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Essential Tremor |
Trial Milestone |
Phase 2 |
| January 15, 2029 |
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer |
Trial Milestone |
Phase 2 |
| January 15, 2029 |
A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA) |
Trial Milestone |
Phase 1 |
| April 15, 2029 |
A Study to Assess the Adverse Events, Change in Disease Activity, and How Oral ABBV-711 Tablets Move Through the Body as a Monotherapy and in Combination With Intravenously Infused Budigalimab (ABBV-181), in Adults With Advanced Squamous Tumors |
Trial Milestone |
Phase 1 |
| April 15, 2029 |
AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension |
Trial Milestone |
Phase 1/Phase 2 |
| May 15, 2029 |
A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer |
Trial Milestone |
Phase 3 |
| June 15, 2029 |
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. |
Trial Milestone |
Phase 3 |
| July 15, 2029 |
Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets |
Trial Milestone |
Phase 1 |
| July 15, 2029 |
A Study to Evaluate Safety and Effectiveness of NOA VOLUME Injectable Gel in Adult Participants Compared to JUVÉDERM VOLUMA XC for Improvement of Mid-Face Volume |
Trial Milestone |
Phase 3 |
| September 15, 2029 |
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis |
Trial Milestone |
Phase 2 |
| November 15, 2029 |
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease |
Trial Milestone |
Phase 2 |
| January 15, 2030 |
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease |
Trial Milestone |
Phase 2 |
| April 15, 2030 |
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata |
Trial Milestone |
Phase 3 |
| October 15, 2030 |
A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease |
Trial Milestone |
Phase 1/Phase 2 |
| December 15, 2030 |
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM) |
Trial Milestone |
Phase 1/Phase 2 |
| December 15, 2030 |
A Study of Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma |
Trial Milestone |
Phase 2 |
| December 15, 2030 |
A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan |
Trial Milestone |
Phase 2 |
| February 15, 2031 |
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants |
Trial Milestone |
Phase 3 |
| July 15, 2031 |
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD |
Trial Milestone |
Phase 2 |
| October 15, 2031 |
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) |
Trial Milestone |
Phase 2/Phase 3 |
| November 15, 2031 |
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM) |
Trial Milestone |
Phase 1 |
| February 15, 2033 |
A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma |
Trial Milestone |
Phase 3 |
| March 15, 2033 |
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) |
Trial Milestone |
Phase 3 |
| September 15, 2033 |
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma |
Trial Milestone |
Phase 1 |
| December 15, 2034 |
Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis |
Trial Milestone |
Phase 3 |
| December 15, 2035 |
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations |
Trial Milestone |
Phase 1/Phase 2 |
| March 15, 2036 |
Study of Intravenously (IV) Infused Etentamig in Combination With an Oral Cereblon E3 Ligase Modulatory Drug (CELMoD) Agent Assessing Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma |
Trial Milestone |
Phase 1 |